After determining the potential prognostic value of SLC35A2 in STAD patients, we further explored the promoter methylation and genetic alterations levels of SLC35A2, to elucidate its relationship with the occurrence and development of cancer. Here, SLC35A2 is linked to gastric adenocarcinoma.